Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of CY-503 (Aviscumine) in unresectable stage IV metastatic melanoma after treatment failure
2007-000427-17Phase 2Completed
- Sponsor
- Cytavis BioPharma
- Start
- Jun 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aviscumine in melanoma, sponsored by Cytavis BioPharma. Primary endpoints: Progression-free survival (median time) and Disease control rate. Started Jun 2007; status: completed.
02
Drugs
aviscumine
03
Conditions
melanoma
Beyond the preview
Go deeper on 2007-000427-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000427-17.